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RESUMO 
O biovidro ativo é um biomaterial promissor que tem mostrado 
excelentes efeitos osteogênicos, angiogênicos e antibacterianos para ser 
aplicado em procedimentos de reparação óssea em diversas áreas. Em 
implantologia oral, infecções podem ocorrer após procedimentos 
cirúrgicos em decorrência da presença de biofilmes orais incluindo 
espécies patogênicas. Sendo assim, este trabalho teve como principal 
objetivo desenvolver biomateriais à base de um biovidro nano-
estruturado para incorporação de compostos com potencial anti-
biofilme. O biovidro ativo 58S foi modificado incorporando brometo, 
compostos derivados do cranberry e da própolis na sua estrutura. As 
amostras foram caracterizadas por meio de análise química, textural e 
física. O potencial anti-biofime do biovidro ativo foi determinado 
através de q-PCR e análise microscópico. A reatividade química foi 
avaliada por meio de análise química, microscópica e da proporção 
Ca/P. As amostras do biovidro ativo incorporando brometo, cranberry 
PACS e própolis mostraram uma distribuição de tamanho de partículas, 
estrutura física e composição química apropriadas. O biovidro ativo 
modificado com 5wt% CaBr2 inibiu a proliferação de S. mitis, V. 
parvula, P. gingivais, S.gordoni, A. viscosus, e F. Nucleatum. Uma 
significativa formação de hidroxiapatita carbonatada foi revelada nas 
amotras do biovidro ativo mesoporoso incorporando cranberry PACS e 
própolis após 72 h de imersão na solução corporal simulada. Por 
conseguinte, a incorporação de compostos inorgânicos e orgânicos no 
biovidro ativo 58S pode ser uma estratégia para potencializar seu efeito 
anti-biofilme e ser aplicado em tratamentos de reparo e infecção óssea.  
Palavras-chave: 1. Biovidro ativo 2. Antibiofilmes 3. Enxerto ósseo 4. 
Sínteses sol-gel 5. Infeção óssea 6. Reparo ósseo 
  
ABSTRACT 
Bioactive glass is an attractive biomaterial that has shown excellent 
osteogenic, angiogenic and antibacterial effects for bone healing. One of 
the main issues regarding oral surgery and bone grafting procedures are 
the recurrent infections caused by oral biofilm involving pathogenic 
species. Thus, the main aim of the present study was to produce porous 
bioactive glasses incorporating inorganic and organic compounds in 
their chemical and physical structure to enhance anti-biofilm potential 
during bone repairing procedures. The modified 58S bioactive glasses 
embedded bromide, cranberry PACS and propolis compounds and were 
characterized through physical, chemical and textural analysis. 
Bioactive glass multispecies antibiofilm potential was evaluated by q-
PCR analysis and microscopic observation. Chemical reactivity of the 
samples was examined through chemical, microscopic and Ca/P ratio 
analysis. Bioactive glasses embedding bromide, cranberry PACS and 
propolis showed an appropriate particle size distribution, chemical and 
physical properties. Bioactive glass embedding 5wt% CaBr2 inhibited S. 
mitis, V. parvula, P. gingivais, S.gordoni, A. viscosus, and F. nucleatum 
proliferation. A significant hydroxyl-carbonate apatite layer was 
revealed by mesoporous BG samples incorporating cranberry PACS and 
propolis compounds after immersion in simulated body fuid for 72 h. 
The incorporation of inorganic and organic compounds into bioactive 
glass structure can be a strategy to enhance its antibiofilm potential for 
bone healing and infection treatment procedures.  
Keywords: 1.Bioactive glass 2. Anti-biofilm agents 3. Bone graft, 4. 
Sol-gel synthesis, 5. Bone infection, 6. Bone repair 
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1 INTRODUÇÃO 
No ano 2012, foi estimado que nos Estados Unidos mais de meio 
milhão de pacientes foram submetidos a cirurgias de enxerto ósseo por 
ano, representando um custo acima de 2,5 bilhões de dólares anuais. 
Espera-se que para o ano 2020 este número de pacientes seja o dobro 
devido ao aumento de expectativa de vida da população mundial 
(AMINI; LAURENCIN; NUKAVARAPU, 2012).  Além do referido, o 
osso é o segundo tecido mais transplantado no mundo depois do sangue 
(JONES, 2013). 
Em decorrência do mencionado, a engenharia tecidual se encontra 
constantemente pressionada pela extensa demanda de cirurgias de 
enxertia óssea. Na área bucal e maxilofacial, procedimentos de enxerto 
ósseo para o reparo e regeneração dos tecidos são utilizados 
frequentemente. Por conseguinte, a procura para desenvolver um 
biomaterial ―ideal‖ para substituir os tecidos ósseos é um tema de 
grande interesse e vários anos de pesquisa.   
Atualmente, os enxertos de origem autógena removidos de um 
leito doador do próprio paciente, são considerados o ―padrão ouro‖ da 
enxertia por ter as características desejadas de osteoindução e 
osteocondução. No entanto, a alta demanda de procedimentos de 
enxertia na região oral dificulta a utilização de osso de origem autógena 
de todos os enxertos devido a fatores limitantes como a necessidade de 
uma área doadora com um volume apropriado, envolvimento de um 
procedimento cirúrgico adicional e aumento da morbidade do paciente 
por ser submetido a um maior número de intervenções. Por outro lado, 
os aloenxertos, removidos e transplantados entre indivíduos de uma 
mesma espécie com características genéticas diferentes, já foram mais 
utilizados no passado. Atualmente são conhecidas desvantagens como a 
reabsorção precoce, potencial de transmissão de proteínas antigênicas e 
doenças infecciosas e a necessidade de um banco de ossos. Por este 
motivo, a engenharia tecidual tem desenvolvido por vários anos diversos 
materiais metálicos, cerâmicos e poliméricos a fim de substituir os 
tecidos ósseos perdidos, considerando que a utilização desses materiais 
depende de propriedades essenciais como a biocompatibilidade, 
bioatividade, estabilidade física e química e propriedades mecânicas 
similares aos tecidos perdidos. Assim, os principais materiais 
aloplásticos cerâmicos que têm sido desenvolvidos a fim de ter as 
características mencionadas são a hidroxiapatita, o beta fosfato tricálcio, 
o fosfato de cálcio bifásico e os biovidros ativos (CRUZ et al., 2006). 
No entanto a procura do biomaterial ―ideal‖ para substituir o tecido 
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ósseo é um constante desafio que a engenharia tecidual enfrenta 
atualmente, já que ainda não existe um biomaterial com as propriedades 
biológicas do tecido autógeno e que contenha biomoléculas capazes de 
induzir a formação óssea (JONES, 2013).  
Além dos fatores biológicos, químicos e mecânicos de um 
biomaterial ―ideal‖, a capacidade antibacteriana e antibiofilme é uma 
característica adicional desejada e requerida nos procedimentos de 
enxertia óssea. A incidência de infecção óssea pós-operatória é 
considerável e é uma complicação frequente das cirurgias orais 
envolvendo enxertia óssea (EL-KADY et al., 2012b; XIE et al., 2009).  
As bactérias organizadas no biofilme  são as protagonistas de 80% das 
infecções humanas (DAVIES, 2003). De modo que a utilização de 
antibiótico terapia é frequente para a prevenção de infecções secundárias 
neste tipo de procedimentos, no entanto o antibiótico não é sempre 
capaz de induzir um efeito efetivo no tecido ósseo infectado já que não 
atua de forma local e atua em uma área com pouca vascularização. 
Adicionalmente,  as bactérias organizadas em biofilme são mil vezes 
mais resistentes ao antibiótico comparadas com as bactérias planctônicas 
(DAVIES, 2003; GALARRAGA-VINUEZA et al., 2017). Assim, um 
biomaterial com propriedades antibiofilme seria capaz de atuar de 
maneira mais eficaz e local na área enxertada infectada.  No entanto, 
poucos materiais têm demostrado capacidade antibacteriana e 
antibiofilme consistente. 
 O biovidro ativo desenvolvido no ano 1969, aplicado em mais de 
um milhão de pacientes no mundo para procedimentos de regeneração 
óssea (HOPPE; GÜLDAL; BOCCACCINI, 2011; JONES, 2013), é um 
biomaterial capaz de inibir o crescimento bacteriano através da liberação 
de íons que elevam o pH do meio e criam um ambiente pouco favorável 
para o crescimento bacteriano (ALLAN; NEWMAN; WILSON, 2002; 
KRISHNAN; LAKSHMI, 2013). Esta característica ambiciosa do 
biovidro, além das suas outras propriedades de promover a osteogênese 
e angiogênese tem posicionado o biovidro ativo como um biomaterial 
promissor (JONES, 2013). Certamente, a capacidade antibacteriana do 
biovidro ativo é de fundamental importância por ter um efeito local 
desejado no leito cirúrgico (BELLANTONE; COLEMAN; HENCH, 
2000; HENCH, 2006). Entretanto, o efeito antibiofilme dos biovidros 
ativos não foi elucidado nem confirmado nos últimos estudos 
(GALARRAGA-VINUEZA et al., 2016), razão pela qual diversas 
pesquisas têm mudado a composição e a estrutura do biovidro ativo a 
fim de conseguir uma maior capacidade antibacteriana e antibiofilme 
(HUM; BOCCACCINI, 2012). Diferentes avanços têm sido 
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apresentados como a incorporação de agentes antibacterianos na 
composição química ou estrutura física do biovidro ativo. Deste modo, 
compostos de prata, céria, selênio, flúor, entre outros têm sido 
adicionados na fórmula química do biovidro ativo a fim de melhorar sua 
capacidade antibacteriana e antibiofilme (MALAVASI et al., 2012; 
STEVANOVIĆ et al., 2015; XU et al., 2015). Por outro lado, a 
tecnologia nano tem mudado a estrutura deste material adicionando 
surfactantes (XIA; CHANG, 2006) na sua fórmula para induzir a 
formação de poros convertendo assim o material num biovidro ativo 
mesoporoso que tem a capacidade de incorporar nos seus nano poros 
substâncias antibacterianas e antibiofilmes como antibióticos, nano 
partículas bioativas e compostos naturais orgânicos (EL-GHANNAM; 
AHMED; OMRAN, 2005; JIA et al., 2010; PRABHU et al., 2014; XIA 
et al., 2008).  
Considerando que ainda não existe um consenso, assim como 
estudos suficientes esclarecendo que tipo de compostos têm efeito 
antibiofilme, o objetivo do presente estudo foi desenvolver e avaliar a 
capacidade antibiofilme do biovidro ativo 58S incorporando compostos 
orgânicos e inorgânicos na sua estrutura química e física.  De tal modo, 
a hipótese do presente estudo é que a incorporação de agentes 
inorgânicos e orgânicos no biovidro ativo potencializará seu efeito 
inibitório do biofilme oral. 
Por conseguinte, o presente manuscrito está divido em três partes, 
sendo a primeira uma revisão da literatura da incorporação de agentes 
antibacterianos e antibiofilmes no biovidro ativo, a segunda descrevendo 
a capacidade antibiofilme do biovidro ativo modificado com brometo de 
cálcio e a terceira mostrando o desenvolvimento e bioatividade do 
biovidro ativo mesoporoso incorporando compostos de origem natural.   
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Abstract:  
Bioactive glasses (BGs) are promising materials for bone repair due to 
their desirable properties such as osteoconductivity, biodegradability, 
angiogenic potential, and antibacterial activity. Ionic dissolution 
products from bioactive glasses increase the medium pH inhibiting 
surrounding bacteria proliferation. The activity of BGs against biofilm 
formation has been enhanced by incorporating organic antibacterial 
compounds. The aim of this review was to summarize evidence in 
literature which assesses the efficacy of antibacterial and anti-biofilm 
compounds embedded in bioactive glasses to prevent peri-implant 
infection during bone healing. A PubMed bibliographical research was 
carried out including articles published in the last 20 years. Most 
previous studies evaluated antibacterial efficiency in planktonic cultures 
but did not investigate biofilm inhibition, underestimating biofilm 
clinical relevance. Multifactorial features such as biocompatibility of 
embedded compounds, receptor site characteristics, and drug delivery 
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efficiency have been found to influence the bioactive glass capability of 
acting both as an anti-biofilm agent and as a bone repairing biomaterial. 
Accordingly, further in vitro and in vivo studies are required to select 
the most promising anti-biofilm agents which should be incorporated 
into bioactive glasses to counteract biofilm proliferation, without 
inducing toxic effects on human cells, and with the added functionality 
of promoting bone regeneration.  
Key Words: bioactive glass, mesoporous materials, antibacterial 
compounds, anti-biofilm activity, drug delivery system 
2.1 INTRODUCTION 
Bone is the second most transplanted tissue in surgical procedures 
worldwide with bone tissue engineering being investigated as a realistic 
alternative for bone healing [1]. Bone tissue engineering often relies on 
an engineered scaffold acting as a temporary extracellular matrix to 
support and deliver cells [2]. Bioactive glasses (BGs) involve a group of 
inorganic biomaterials discovered in the late 1960s that have been 
applied in bone repair due to their bioactivity, osteogenic, and 
angiogenic potential, biodegradability, and osteoconductivity [3]. BGs 
stimulate diverse biologic responses in contact with physiological fluids, 
such as the development of a carbonated hydroxyl-apatite (CHA) 
surface layer that is comparable to the mineral phase of bone and acts as 
an interface to enhance the attachment of bone cells. BGs also possess 
antibacterial potential due to their high surface reactivity and ion release 
capability [4, 5] causing high aqueous pH values in the surrounding 
tissues; however, such antibacterial effect has been reported to be 
restricted to certain planktonic bacteria [6–11]. Consequently, various 
approaches have been put forward for the incorporation of additional 
antibacterial compounds into BG compositions to enhance antibacterial 
and anti-biofilm activity, this being the subject of the present review.  
Biofilm is a multi-species agglomerate of microbial cells 
enclosed in a well-organized extracellular polymeric substance (EPS) 
matrix that adheres to soft and hard surfaces. The EPS matrix allows 
genetic information exchange and chemical signaling between microbial 
cells through a mechanism known as quorum sensing. Biofilms act as a 
biological barrier against therapeutic agents and host immune cells; 
retaining also nutrients from the environment [12,14]. Biofilms 
containing pathogenic species are reported to cause over 80% of human 
infections [12–14]. Oral biofilms adhere to different surfaces of 
prostheses, implants, mucosa, teeth, and bone. Biofilm formation is a 
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gradual process consisting of four distinct stages [13–15]: (a) acquired 
pellicle formation; (b) primary (early) colonization; (c) secondary 
colonization/ co-aggregation; and (d) mature biofilm establishment. The 
early colonization begins through binding primary bacteria to a 
conditioning film composed of glycoproteins, water and nutrients, that is 
previously established in the mouth. The first adherent oral bacteria 
(Streptococcus sanguinis, S. oralis, S. gordonii, S. mitis, Actinomyces 
naeslundii, Capnocytophagaochraceae, S. mutans and S. sobrinus) are 
weakly and reversibly linked to glycoproteins named by adhesins, 
although they may remain and proliferate, starting the phenomena of 
microbial co-aggregation. Steptococcus species represent 60–80% of all 
primary colonizers. Such coaggregation is mediated by metabolic and 
genetic exchange known as quorum sensing. The secondary colonization 
occurs within 3–5 days after the beginning of the early colonization. In 
this process, the microorganisms start to multiply and to co-aggregate 
with partner species leading to the biofilm structural organization. 
Microorganisms organized in biofilms achieve a strong adherence to 
oral surfaces leading to a maturation process within 2–3 weeks [12–15]. 
 Previous studies have described that biofilms are about one 
thousand times more resistant to antibiotic therapy compared to free 
floating planktonic bacteria [12, 15]. In addition, studies have described 
that conventional systemic antibiotic therapy is not as effective as 
expected to eradicate bone infection because antibiotics do not act 
locally in septic areas and they may induce side effects in patients 
[13,16]. In the last decade, sol-gel derived mesoporous bioactive glasses 
(MBGs) have been developed with the purpose of becoming carriers for 
therapeutic agents acting as drug delivery systems [17–20]. 
Consequently, MBGs are advantageous candidates for both bone repair 
and peri-implant infection treatment since they combine unique 
properties to stimulate bone growth and prevent bacteria proliferation.  
The present review assesses antibacterial and antibiofilm efficacy 
of BG carriers embedding organic compounds focusing on multifactorial 
parameters that can control antibacterial effects during bone healing. A 
PubMed electronic search including articles published in the last 20 
years was performed using the following combination of key words and 
MeSH terms: ―bioactive glass‖ or ―Bioglass‖ and ―antibacterial‖ or 
―anti-infective‖ or ―antibiotics‖ or ―antibacterial‖ or ―biofilm 
inhibition‖. The selection criteria identified papers describing in vitro 
and in vivo studies, thus only articles that evaluated specifically 
antibacterial or anti-biofilm effects of bioactive glasses embedding 
antibacterial compounds were reviewed and discussed. The present 
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article is not intended to be comprehensive in terms of the number of 
studies included; it is rather a discussion article containing the relevant 
information found in key publications to provide the reader with initial 
points for further analysis.  
2.2 ORGANIC AGENTS INCORPORATED INTO BIOACTIVE 
GLASS  
In the last years, several studies have shown proper antibacterial 
properties achieved by different formulations of bioactive glasses 
incorporating several oxides [21–23] and the effects of biologically 
active ions on bone tissue engineering have been discussed in literature 
[24]. In addition, commercial products based on bioactive glass (melt-
derived, composition SiO2 53%, Na2O 23%, CaO 20%, P2O5 4%) are 
being successfully applied in the clinic to treat osteomyelitis [25] and 
the application of BGs to treat bone infections by the effect of pH 
increase is well demonstrated in literature [4,6,26,27]. Recent studies 
describe the incorporation of triclosan 28 into BG considering that this 
compound has already been applied in mouthwash solutions for clinical 
considerations involving biofilm-induced infections. Xu et al. reported 
in vitro antibacterial effects of 45S5 BG embedding triclosan against 
cariogenic S. mutans biofilm [29]. This study assessed anti-biofilm 
activity by pouring BG powders incorporating triclosan into wells 
containing S. mutans biofilm plaques that had undergone 6, 12, and 24 h 
of growth conditions. After 10 min of exposure, each coverslip 
containing biofilm was washed with PBS and centrifuged in saline 
solution. Subsequently, S. mutans biofilm was detached from the cover 
slips and then incubated in agar plates for 48 h at 37◦C, simulating oral 
conditions. Biofilm viable colonies were counted and observed using a 
stereomicroscope and scanning electron microscope. The study showed 
additive anti-biofilm effects when BG was combined with triclosan. 
Pertinently, this previous study focused on the assessment of anti-
biofilm activity rather than antibacterial effect against planktonic 
cultures. However, this broad-spectrum antibacterial agent is 
hydrophobic and can accumulate in human fatty tissues, breast milk, 
urine, and serum [30]. Furthermore, that synthetic organic agent has 
been reported to cause endocrine disruption in mammals, affecting the 
thyroid hormone reproduction and its homeostasis, [31] so that further 
research on triclosan containing BGs will have to investigate possible 
negative effect of its use.  
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Natural organic compounds derived from medicinal plants known 
as phytotherapeutics can promote both antibacterial and anti-
inflammatory activity [32]. The scientific interest in natural active 
compounds has increased for biomedical applications, since they are 
well-known health-promoting agents and produce minimum side effects. 
Essential oils derived from plants have numerous desirable properties 
being antibacterial, antiviral, antifungal, and having insecticide potential 
[33]. Regarding natural organic compounds as favorable antibacterial 
agents in combination with BGs, Prahbu et al. [34] studied the in vitro 
antimicrobial effect of BGs of composition (58SiO2-33CaO-9P2O5) 
incorporating neem plant (Azadirachta indica) leaf powder, a natural 
antiviral and antibacterial compound against a broad spectrum of 
bacteria [35]. BG nanoparticles (NPs) doped with neems leaf powder 
were analyzed by using Kirby-Bauer disc diffusion method and 
exhibited considerable antimicrobial activity against S. aureus and E. 
coli cultures. Additionally, neem doped BG NPs demonstrated superior 
antibacterial properties against Gram-positive and Gram-negative 
bacteria in comparison to those recorded for silver doped or pure BG 
NPs. Besides the beneficial antibacterial effect, neem-doped BG 
nanoparticles were analyzed by MTT assay and exhibited reduced 
cytotoxic effects. Results of that study established that neem doped BG 
was a biocompatible and potent antibiofilm agent for tissue engineering 
applications [34].  
An alternatiive approach toward incorporating natural organic 
compounds into BGs was performed by Bonfim et al. [36]. In this study, 
Brazilian red and green propolis were incorporated into BGs of 
composition (SiO2)0.80(P2O5)0.04(CaO)0.16. Propolis, a natural non-
toxic beehive agent found in honeycombs, has antifungal and antiviral 
properties as well as antibacterial activity against a wide range of cocci 
and Gram-negative rods [37]. Propolis solution was added during the 
BG sol-gel synthesis to obtain specimens for antimicrobial assays. The 
in vitro study reported growth inhibition on the following pathogenic 
species: S. aureus, E. faecalis, S. mutans, P. intermedia, F. nucleatum, 
P. gingivalis, and A. actinomycetemcomitans [36]. Accordingly, propolis 
is considered an antibacterial natural compound of high potential for 
future developments given its ability to inhibit bacterial adherence, 
prevent biofilm accumulation, and to reduce virulence factors of S. 
mutans [38]. Also, Propolis has been evaluated in previous studies 
showing a noncytotoxic nature [39, 40]. Grenho et al. [41] reported that 
propolis had antibacterial effectiveness and exhibited bioactive 
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characteristics such as stimulation of fibroblast migration, high cell 
metabolic activity, and absence of cell membrane damage. 
 Despite the success reported by some investigations mentioned 
above, organic compounds, especially natural derived agents like 
phytotherapeutics have not been largely explored to date in combination 
with BGs. Since BGs have the ability to incorporate both hydrophilic 
and hydrophobic groups in their structures, in vitro and in vivo studies 
involving natural organic compounds bound to BGs are expected to 
increase. Considering that various nature derived agents have reduced or 
non-cytotoxic effects [32–34,40] future investigations involving also 
clinical trials should be performed to identify the advantages and 
synergies brought by the combination of natural organic compounds and 
BGs to avoid peri-implant infections.  
2.3 BIOACTIVE GLASS AS AN ANTIBIOTIC DELIVERY 
SYSTEM  
In the last 15 years, BGs have been increasingly considered as 
vehicles for the local delivery of drugs, growth factors, and antibiotics 
[17–19, 42–45]. Tissue engineering approaches using BG scaffolds, 
which include a therapeutic drug or antibiotic delivery capability are 
based on multifunctional scaffolds, which are capable of releasing 
therapeutic substances against microbial infections in a controlled 
manner during the process of tissue repair [17, 42, 43, 45–48]. Systemic 
antibiotic therapy is not always effective to treat bone infections since 
there is vascular insufficiency and antibiotics may not arrive to infected 
areas through the blood stream. On systemic therapy, antibiotic 
biomolecules can be inactivated in the blood stream and may have no 
effect where they are needed at the implanted sites [8, 17]. In cases of 
bone repair procedures, there is a high incidence of infection and 
inflammatory response caused by host immune reactions. Attempting to 
solve implantation site complications, BG carriers with well-organized 
mesoporous structures are developed [18–20, 44, 45] which exhibit 
adjustable pore diameter and high surface area where antibiotics can be 
encapsulated for their controlled delivery. A previous study involving 
MBG reported a continuous release of gentamicin for six days inhibiting 
bacterial adhesion and biofilm formation of S. aureus and S. epidermis, 
which are prevalent species at implant infections [44].  
Similarly, Xie et al. [46] preformed an in vivo study to evaluate 
the antibacterial effect of loaded gentamicin pellets composed of 
chitosan and borate-based BG. A bone tissue infection (osteomyelitis) 
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associated to Gram-negative bacilli was induced in a rabbit tibia model 
and then treated by the application of gentamicin-loaded BG pellets. 
Results from microbiological, radiographical, and histological assays 
stated an eradication of 81.82% infected cases. That study indicated that 
gentamicin-loaded BG pellets are attractive materials for osteomyelitis 
treatment. In addition, related in vivo studies performed by Nandi et 
al.[47] reported control of bone resorption in experimental osteomyelitis 
and consequent formation of lamellar bone by using cefuroxime axetil 
(CFA)-loaded MBG.  
The results of several studies have thus indicated that local 
antibiotic release from MBGs can be a solution to treat bone infection. 
Various antibiotics such as carbeinicillin, [48] ciprofloxacin, [49] 
tetracycline hydrochloride (TCH), [50,51] vancomycin, [52,53] and 
teicoplanin [54] have been incorporated into BGs, as summarized in 
Table I. Nevertheless, biofilm infections at receptor sites are resistant to 
several antibiotics due to the presence of pathogenic species in well-
organized extracellular matrices [12]. Rastegar et al. [55] reported that 
P. aureginosa, a specie associated to the formation of biofilm on 
implanted devices, was resistant to carbenicillin, cotrimoxazole, 
ceftizoxime, gentamicin, and tetracycline in 95% of the cases of wound 
infections. On a comparative study of antibiotic resistance between 
planktonic bacteria and biofilm cultures, Olson et al. [13] found that the 
minimum biofilm inhibitory concentrations of cloxacillin, amoxicillin, 
gentamicin, ampicillin, tetracycline, penicillin G, and ceftiofur were not 
able to eradicate biofilms formed by A. pyogenes, S. aureus, S. hyicus, S. 
agalactiae, C. renale, and C. pseudotuberculosis. However, it was 
shown that planktonic cultures were susceptible to several antibiotics. 
Considering the clinical relevance of biofilm resistance to antibiotics, 
incorporating anti-biofilm compounds rather than antibiotics into BGs 
represents a more effective approach that should be explored more 
intensively in future. Further studies are required to understand and 
characterize factors involved in biofilm growth, microbial gene 
exchange, and bacteria communication to develop new anti-infective 
chemotherapies, which can involve BGs loaded with antibiofilm agents. 
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Table I. Summary of Relevant Studies on Antibiotic-Loaded Bioactive Glasses to Prevent Infection 
Study/ Experimental 
design 
BG  composition  Loaded Antibiotic 
Outcome 
Antibacterial Effect Targeted 
bacterias 
Li et al. (LI et al., 
2013) 
In vitro 
Mesoporous BG * Gentamicin Inhibition of bacterial adhesion and 
biofilm formation 
S. aureus  
S. epidermis 
Xie et al. (XIE et al., 
2009a) 
In vitro/ in vivo 
(osteomyelitis 
induced in an animal 
model) 
Pellets of chitosan-
bonded with borate BG 
[mol%] 6Na2O,8K2O, 8 
MgO, 22 CaO, 54 B2O3, 
2P2O5 
Gentamicin  In vitro:  
Inhibition of bacterial growth 
In vivo:  
6 weeks after implantation, 9 out of 
11 rabbits were 
negative for E. coli by culture 
analysis. 
Eradication of 81.82% of bone 
infection cases demonstrated by 
radiographic, histopathologic, and 
microbiological examinations. 
E. coli  
 Miola et al. (MIOLA 
et al., 2013) 
In vitro 
BG [mol%] 
45SiO2,3P2O5, 26CaO, 
7MgO, 15Na2O, 4K2O 
Carbenicillin  Samples released an antibiotic 
amount considerably higher than S. 
aureus MIC (minimum inhibitory 
concentration) of carbenicillin. 
N.A.  
Mabrouk et al. 
(MABROUK et al., 
2014) 
In vitro 
Composite scaffolds of 
polyvinyl alcohol and 
quaternary 46S6 BG 
[mol%] 46SiO2, 24 CaO, 
24Na2O, 6P2O5 
Ciprofloxacin  N.A. N.A. 
Rivadeneira et al. BG 45S5 Tetracycline Bacterial cell growth inhibition, 4 staphylococci 
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(RIVADENEIRA et 
al., 2014) 
In vitro 
nanoparticles/collagen 
composites [mol%] 
45SiO2, 24Na2O, 
24CaO, 6P2O5 
hydrochloride 
(TCH)   
antibacterial efficacy was similar for 
all TCH concentrations: 0.05, 0.20, 
0.35 mg ml 
-1
 
strains: S. aureus 
ATCC29213, 
ATCC25923, 
ATCC6538P and 
S. epidermidis 
ATCC12228. 
Domingues et al. 
(DOMINGUES et al., 
2004) 
In vitro/ In vivo 
(animal model) 
BG [mol%] 80SiO2, 16 
CaO, 4P2O5 
 
- Tetracycline 
hydrochloride (BT) 
-Complex formed 
by tetracycline and 
beta-cyclodextrin 
(BTC) 
-A significant bacteriostatic activity 
was found with BT and BTC glasses. 
-Cyclodextrin slowed down the 
release of tetracycline for a long 
period of time. 
-Bactericidal activity increased when 
BG was loaded with tetracycline 
A. 
actinomycetemco
mitans 
Rivadeneira et 
al.(RIVADENEIRA et 
al., 2015) 
In vitro 
Agar–gelatin (AG) 45S5 
BG microparticles 
composites 
[mol%] 45SiO2, 
24Na2O, 24CaO, 6P2O5 
Vancomycin 
hydrochloride (VC)  
-Bacterial cell viability for S. aureus 
ATCC6538 was considerably 
inhibited  
after 24 and 48h of incubation. 
-AG-BG samples loaded with VC 
did not reduce the number of 
bacteria below 10
5
 
cfu (colony forming units) 
ml
−1
 
3 staphylococcus 
strains:  
S. aureus 
ATCC29213, S. 
aureus 
ATCC6538, and  
S. epidermidis 
ATCC12228.  
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Yao et al. (YAO et al., 
2013) 
In vitro 
45S5 BG scaffolds 
coated with 
polycaprolactone and 
vancomycin-loaded 
chitosan, [mol%] 
45SiO2,24Na2O, 24CaO, 
6P2O5 
Vancomycin  N.A. N.A. 
Jia et al. (JIA et al., 
2010) 
In vitro/in vivo 
(osteomyelitis 
induced in an animal 
model) 
Borate BG and chitosan 
composite [mol.%] 
6Na2O, 8K2O, 8MgO, 
22CaO, 54B2O3, 2P2O5 
Teicoplanin  
(TBGC) 
In vivo: efficient therapeutic effect 
was revealed in animals implanted 
with TBGC pellets, showing an 
inferior positive rate of MRSA 
culture. 
Methicillin-
resistant S. 
aureus 
(MRSA) 
* BG composition is not specified in the study. N.A.: not applied, study has not performed specific antibacterial tests
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2.4 MULTIFACTORIAL ASPECTS INFLUENCING BIOACTIVE 
GLASS TO EMBED BIOFILM INHIBITORS  
Biofilms in infected implanted tissues have an unquestionable 
clinical significance; for that reason, clinical guidelines involving 
effective protocols and superior biomaterials must be established for 
infection management. It is remarkable that the majority of studies 
dealing with antibacterial materials does not mention or consider in 
detail antibacterial activity. In general, studies show proper antibacterial 
activity against planktonic bacteria. Those studies suggest that a 
―proper‖ antibacterial activity is necessary for should be considered for 
future medical applications in bone infection therapy [4, 56]. However, 
it can be considered a controversial issue if the antibacterial effect 
achieved in those studies is sufficiently effective to treat human 
infections [57]. Other previous studies have evaluated anti-biofilm 
activity against mono-species biofilm formation [29, 58]. Perez-Tanoira 
et al. for example, reported that S53P4 BG prevented bacterial and 
biofilm adhesion, however this study; nevertheless, this study tested 
solely staphylococcal biofilm inhibition. Other recent studies have tested 
anti-biofilm properties of compounds against multi-species biofilms. 
Bortolin et al [59] revealed that S53P4 BG was able to reduce biofilm 
composed of S. epidermis, A. baumanii, and K. pneumoniae. 
Furthermore, Drago et al. [60] reported that S53P4 BG revealed a 
relevant biofilm inhibition effect on S. aureus and P. aureginosa. In 
principle, even if studies that analyze antibiofilm effects are reliable; 
increased efforts involving in vivo studies are needed to simulate 
realistic human infection conditions.  
Human body infections, especially bone infections, are complex, 
and cannot be controlled by antibacterial effects solely. In general, bone 
infections are hard to treat due to diverse biological factors, notably 
vascular insufficiency, where systemic antibiotics and host immune cells 
are not able to reach the infected area through the blood stream.16 In 
addition, bone infections induced by multi-species biofilm formation 
increase antibiotic resistance and bacteria pathogenicity.12,15 
Accordingly, bone infection treatment should focus primarily on 
inhibiting biofilm formation [61]. Nowadays, there are limited effective 
therapies specifically targeting biofilm formation. Mechanical 
debridement for infected bone removal is the most accepted clinical 
procedure [16]. Therefore, if bone debridement could be complemented 
by the application of an efficient anti-biofilm agent, for example based 
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on mesoporous bioactive glasses as discussed in this review, such 
biomaterial will be a promising candidate for bone infection treatment, 
as schematically illustrated in Figure 1. 
 
Figure 1. Schematic diagram showing mesoporous BG loaded with 
antibacterial agents applied and delivered at infected implanted receptor sites 
with an acid medium to inhibit biofilm proliferation and repair bone defects. 
Another factor to consider is the type of active compound 
embedded into the BG carrier. As mentioned above, studies have been 
performed involving natural organic compounds such as essential oils 
and phototherapeutics as essential oils, which appear as valid 
alternatives for synthetic drugs [34, 36]. Consequently, new challenges 
have emerged to incorporate natural derived agents into BG 
compositions with the purpose of inducing antibacterial and health-
promoting effects at receptor sites. Additionally, MBGs with highly 
organized structure have been reported to favor angiogenic and 
osteogenic responses [17, 20, 62]. For this reason, promising future 
approaches should consider MBG advantages and develop mechanisms 
to encapsulate pharmacological agents based on phytotherapeutics into 
wellorganized MBGs to enhance bone repair, inhibit biofilm formation, 
and reduce toxic effects. Indeed understanding the synergetic effects of 
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the release of both therapeutic ions and organic antibacterial agents 
remains a subject of high interest for future studies.  
In this context, identifying parameters that influence the 
performance of MBGs as drug carriers is crucial to improve their action 
in infected receptor areas. Bone receptor surgical sites are inflammatory 
acidic areas where local acidosis increases due to the presence of 
bacterial metabolism byproducts like fatty acids and lactic acid 
produced infiltrated neutrophils [63]. MBG based drug delivery systems 
could take advantage of this acidic condition when applied on infected 
receptor areas and become a pH sensitive drug delivery structure, as 
schematically shown in Figure 13, [64]. Previous studies have shown 
that gentamicin released from MBG is pH dependent. Xia et al.64 
reported MBGs as dual drug delivery systems where individual drugs 
could be released at different rates depending on the pH values of the 
surrounding area. Also, another study [65] established that gentamicin-
loaded MBG exhibited drug release sensitive to the pH and the ionic 
composition of the surrounding medium. Consequently, significant 
features from receptor implanted sites such as biofilm accumulation and 
infiltrated inflammatory cells should be considered in forthcoming 
studies to enhance the capabilities of BGs as controlled delivery systems 
for anti-infective agents that can possess continuous action and efficient 
release.  
2.5 CONCLUSIONS AND OUTLOOK  
The majority of the reviewed scientific literature in the field of 
antibacterial materials has focused on in vitro and in vivo assays in 
specific models. Furthermore, most of the studies assessed antibacterial 
efficiency in planktonic bacteria cultures, which do not mimic a genuine 
infected tissue environment. Underestimation of biofilm significance in 
bone infection and repair procedures is a matter of concern, since studies 
may represent unrealistic conditions and they could be assessing 
antibacterial agents that may be inefficient or do not have the desired 
effects in future clinical applications. In fact, diverse multifactorial 
features influence the bioactive glass capability of being simultaneously 
an antibacterial, antibiofilm, and repairing biomaterial. Such factors 
involve incorporation of different biocompatible organic compounds 
with antibacterial and anti-biofilm potential, evaluation of receptor site 
conditions, drug delivery efficiency, and understanding synergetic 
effects with the intrinsic metallic ion release capability of BGs in the 
context of osteogenic and angiogenic response. The mentioned 
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characteristics can improve BGs making them biomaterials of choice for 
bone infection treatment and bone repair applications. In this context, 
further comprehensive in vitro and in vivo studies applying mesoporous 
bioactive glass incorporating effective anti-biofilm compounds at 
infected receptor sites are required.  
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Abstract:  
Bioactive glass is an attractive biomaterial that has shown excellent 
osteogenic and angiogenic effects for oral bone repairing procedures. 
However, anti-biofilm potential related to such biomaterial has not been 
completely validated, mainly against multi species biofilms involved in 
early tissue infections. The aim of the present study was to evaluate the 
anti-biofilm effect of 58S bioactive glass embedding calcium bromide 
compounds at different concentrations. Bioactive glass containing 0, 5, 
or 10wt% CaBr2 was synthesized by alkali sol-gel method and then 
characterized by physco-chemical and scanning electron microscopy 
(SEM). Then, samples were tested by microbiological assays using 
optical density, real time q-PCR, and SEM. Bioactive glass particles 
showed accurate chemical composition and an angular shape with a 
bimodal size distribution ranging from 0.6 to 110 µm. The mean particle 
size was around 29 µm. A significant anti-biofilm effect was recorded 
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for 5wt% CaBr2-doped bioactive glass against S. mitis, V. parvula, P. 
gingivais, S. gordoni, A. viscosus, and F. nucleatum. Such species are 
involved in the biofilm structure related to infections on hard and soft 
tissues in the oral cavity. The incorporation of calcium bromide into 
bioactive glass can be a strategy to enhance the anti-biofilm potential of 
bioactive glasses for bone healing and infection treatment.   
Key words: Bioactive glass, anti-biofilm, bromide, sol-gel synthesis, 
bone infection, bone healing   
3.1 INTRODUCTION  
Bioactive glass (BG) is a promising biomaterial developed 40 
years ago by the American scientist Larry Hench who produced the first 
BG of 45S5 composition with the purpose of repairing human bone 
defects and derived infections [1,2]. Previous studies have widely shown 
the outstanding properties on 45S5 BG, such as stimulation of 
osteogenic cell migration, vascularization, dissolution in bone tissue, 
and antibacterial effects induced by ion release [3]. In the 90s, a 
bioactive glass named 58S was developed via sol-gel method, in order to 
obtain an alternative compound with similar properties to those recorded 
for 45S5. Sepulveda et al. showed that melt-derived 45S5 BG powders 
exhibited lower dissolution rates for hydroxyapatite formation in 
comparison to those on 58S sol gel-glass powder [4]. Accordingly, 
hydroxyapatite is fundamental for bone healing and remodeling. Thus, 
the formation of a carbonated hydroxyl-apatite (CHA) layer establishes 
a bioactive interface between bone and BG surface, mimicking the 
mineral phase of bone, that also induces osteogenic cell proliferation, 
resulting in a desired biological match between BG particles and human 
tissues [1,5,6]. Nonetheless, proper bioactive response is only one of the 
purposes of a bioactive material. Bone infection occurs in the range of 
1-2.5% being an issue of orthopedic and oral surgeries [5,7,8]. In fact, 
biofilms are responsible for more than 80% of human infections [9,10] 
which influence the clinical use of antibiotics after surgical procedures.  
The antibacterial effect revealed by BG has been attributed to the 
ion release capability in increasing the pH of the surrounding medium 
that can affect planktonic bacteria growth [11]. Most of the studies 
report that the BG antibacterial effect against specific planktonic 
bacteria do not reflect realistic conditions of biofilm growth and 
pathogenicity at infected areas [12–16]. Biofilm is a well-organized 
microbial community embedded in an extracellular polymeric matrix 
57 
composed of polysaccharides, nucleic acids, proteins and water, that 
adheres to different surfaces  
such as teeth, rehabilitation synthetic materials, bone, and soft 
tissues [17,18]. As a result of a complex well-organized structure, 
bacteria embedded in biofilm is 1000 times more resistant to antibiotic 
therapy compared to planktonic bacteria [9,12]. Additionally, studies 
have shown that biofilm formation may enhance virulence of certain 
pathogenic bacteria like P. gingivais [19], S. mitis, F. nucleatum, A. 
viscosus, A. actinomycetemcomitans, and V. parvula [20].  In an attempt 
in improving BG antibacterial and anti-biofilm activity, several studies 
have reported positive antibacterial properties achieved by bioactive 
glasses embedded with inorganic compounds containing silver, cerium, 
selenium, magnesium, zinc, or fluoride [14,15,21–24]. Bromine, a 
chemical element corresponding to the halogen group, has been poorly 
explored in tissue engineering applications. One study reports the 
application of 12-methacryloyloxydodecylpyridinium bromide (MDPB) 
monomer as an antibacterial agent embedded in resinous biomaterials. 
That previous study reported an effective antibacterial and anti-biofilm 
activity of MDPB against S. mutans species over a period of 60 s. That 
was attributed to the inhibition of an enzyme named lactate 
dehydrogenase activitywhich is responsible for the S. mutans 
metabolism [25].  
Nevertheless, there are no studies reporting the incorporation of 
CaBr2-based compounds in BG composition to enhance its antibacterial 
activity. Therefore, the aim of the present study was to produce a 
bioactive glass embedding calcium bromide as an innovative strategy to 
inhibit biofilm formation avoiding infections at bone and surrounding 
tissues. The null hypothesis of this study was that the presence of 
bromide does not affect the multi-species biofilm growth on 58S 
bioactive glass.    
3.2 MATERIALS AND METHODS    
The methodology applied in this study to synthesize and analyze 
58S bioactive glass embedding CaBr2 is represented in Figure 1. First, 
BG (58 wt% SiO2, 33 wt% CaO, 9 wt% P2O5) powder was processed by 
sol-gel method following a previous study performed by the authors 
[26]. For that, tetraethyl orthosilicate (TEOS) (98%, Sigma Aldrich, 
USA), triethyl phosphate (TEP) (99.8%, Sigma Aldrich, USA) and 
calcium nitrate tetrahydrate (Ca(NO3)2·4H2O) (Vetec, Brazil) were used 
as precursors of silicon, phosphorous and calcium oxide, respectively. 
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Nitric acid (HNO3, 68%, Vetec, Brazil) was used to dissolve 
Ca(NO3)2·4H2O and to adjust pH solution while ethyl alcohol (EtOH, 
P.A., Synth, Brazil) was used to dissolve TEOS and TEP. Molar ratio of 
SiO2, P2O5 and CaO was calculated, concerning the BG58S proportion. 
TEOS and TEP were placed in a glass recipient containing EtOH under 
magnetic stirring at 25 
o
C for 10 min. Ca(NO3)2·4H2O was dissolved in 
2 M HNO3 and then added to water at a molar ratio TEOS:H2O of 1:4. 
For bromide doped BG58S samples, calcium bromide hydrate 
(CaBr2.xH2O, Sigma-Aldrich, USA) was added as bromide precursor to 
achieve 5 or 10 wt% CaBr2. Considering the stoichiometric relation of 
calcium bromide, calcium nitrate quantity was calculated to maintain the 
final amount of 33wt% CaO. The mixtures were added to the solution 
and stirred for 1 h. Solution was placed in a chamber at 70 °C for drying 
over a period of 24 h. Subsequently, the material was thermally treated 
at 600 °C and milled in planetarium ball mill (PM100, Retsch, 
Germany) at 400 rpm for 1 h, to obtain the bioactive glass powder.  BG 
powders were deagglomerated in a mortar agate with acetone. Then, BG 
powders were sieved at 106 µm and pressed at 80 MPa to obtain small 
discs of 10 mm diameter and 1 mm thickness. Thermal treatment was 
performed at 1150ºC, by 10 ºC/min heating rate and 180 min of holding 
time.   
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Figure 1. Schematic diagram showing the followed methodology to assess 
biofilm inhibition 
Physico-chemical and morphological analyses  
An initial chemical analysis was performed by energy dispersive 
X-ray spectroscopy (EDX, Swift 2000, Hitachi, Japan). The compound 
composition was obtained by rearranging the quantity of oxygen to 
calculate the weight percentage of oxides using the most stable 
stoichiometric arrangement, resulting in a reliable tool to semi-quantify 
the respective oxides. To evaluate the density of the sintered samples, 
the Archimedes Principle was applied to measure the relative density of 
the discs in green and after thermal treatment at 1150 ºC. The particle 
size distribution was measured in a laser diffraction equipment 
(Mastersizer 2000, Malvern, UK). The powder was introduced in a wet 
dispersion unit with low water rotation around 1200 rpm to avoid any 
deagglomeration of the sample. Before microbiological assays, the 
morphologic aspects of the BG particles as well as the surfaces of the 
test samples were analyzed by scanning electron microscopy (SEM), 
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(TM3030, Hitachi, Japan) at 15 kV by back-scattering electron (BSE) 
mode. Samples were sputter-coated with gold prior to SEM analysis. 
The roughness values of the disc samples were obtained regarding Rt 
(maximum height between peak and valley) and Ra roughness 
parameter that consists in the arithmetic mean value between the peak 
and valley height values in the effective roughness profile. The Ra 
roughness was recorded at five different areas on each material (n=25) 
using an optical profilometer (Zygo, NewView, 7300, USA). The 
measurement length was 0.7 mm and cut off at 0.25 mm for 3 s. 
Afterwards, a color map and 3D model representation of the surface 
roughness was performed per each sample using the Mountain map 
Software (Digital Surf, France).  The X-ray diffraction (XRD) analysis 
was performed on the powder and thermal treated samples to evaluate 
the presence of crystalline phases in the amorphous matrix of the 
bioactive glass. The samples were analyzed in a diffractometer (D8 
Discover, Bruker, Germany) by using Cu Kα radiation (λ = 1.5406 Å) 
on theta-2 theta mode. The range of analyzed angles was at 10-70º, with 
a step size of 0.04º and 1 s of step time. The peaks for each phase were 
identified using X’Pert High Score Plus Software (Panalytical, USA) 
within JCPDS patterns database.   
Biofilm growth conditions  
Bioglass discs with different concentrations of CaBr2 (0%, 5% or 
10%), were tested against a multi-species biofilm, grown in a bioreactor 
(BIOSTAT® B, Germany) simulating the oral conditions as illustrated 
Figure 1. The multi-species form included 10 strains as follow: 2 early 
colonizer bacterial species (Streptococcus mitis and Streptococcus 
gordonii), 5 pathogen bacterial species (Fusobacterium nucleatum, 
Porphyromonas gingivalis, Prevotella intermedia, Streptococcus 
mutans, Streptococcus sobrinus) and 3 beneficial bacterial species 
(Veillonella parvula, Actinomyces viscosus, Streptococcus salivarius). 
750ml of BHI II [27] 37 g/L containing brain heart infusion broth, 2.5 
g/L mucin from porcine stomach type III (Sigma-Aldrich Chemie 
GmbH, Buchs, Switzerland), 1g/L yeast extract, 0.1 g/L L-cysteine, 2 
g/L sodium bicarbonate was added to the bioreactor vessel.  Also, the 
calibration of pH electrode was performed with 1/10 HCl 1/10 and the 1 
molar NaOCl before the sterilization process. Yet, one vessel of 2L was 
prepared with fresh BHI II, in order to be able to refresh the growth 
medium twice a day, over the experiment period. After the sterilization 
process, the bioreactor was set-up with 300 rpm of stirring on anaerobic 
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condition at 37°C. Also, an anti-foam liquid was added before the 
overnight wait.  
Bacterial strains were grown overnight at 37°C in BHI under 
aerobic or anaerobic conditions, as described in the ATCC 
recommendations for each strain and then incubated in the bioreactor. 
After 24 h, the bioreactor medium was supplemented with 5 mg/L 
hemin, 1 mg/L menadione, and the absorbance of medium was adjusted 
to zero. After this procedure, the absorbance of the bacterial suspension 
was controlled to achieve the same optical density values prior to 
incubation in the bioreactor. Stable multi-species biofilm were obtained 
for 72 h. After this period, BG discs were placed at the bottom of 24 
well-plates. Each well containing a BG disc was filled-up with 900 µL 
fresh BHI and 100 µL bioreactor culture. The negative and positive 
control groups had pure bioglass discs. However, the negative control 
group received 900 µL fresh BHI and 100 µL bioreactor culture while 
the positive control group was tested with 400 µL chlorhexidine, 500 µL 
fresh BHI and 100 bioreactor culture.  The 24 well plates were 
incubated at 37°C under anaerobic conditions over a period of 24 h 
biofilm growth. Then, the supernatant was carefully removed with 
pipets, and therefore the discs were smoothly cleaned two times with 
300 µL PBS to withdrawn the weakly attached biofilm. The well-
attached biofilm was removed with 300 µL trypsin, into an anaerobic jar 
and maintained into the incubator for 15 min. The trypsin from each 
well was added to Eppendorf’s to be centrifuged and then the pellets 
were resuspended in 500 µL PBS. On such dilution, a vitality DNA 
extraction was performed using 10 µL PMA and 90 µL bacterial 
dilution in PBS. The real time q-PCR was performed in triplicate for 
each strain using the ABI 7700 Sequence Detection System platform 
(Applied Biosystems, Foster City, CA, USA) [28]. Data was exported to 
an excel sheet to analyze the amount of each strain into the biofilm. For 
microscopic analyses, discs covered with biofilms were washed two 
times in PBS and fixed in glutaraldehyde 2% for 5 min. Then, discs 
were washed three times in PBS, and dehydrated through a series of 
graded ethanol solutions (50, 70, 80, 90, 100%). Samples covered with 
biofilms were sputter-coated with gold, and analyzed by scanning 
electron microscopy.   
3.3 RESULTS    
The particle size distribution of BG58S particles revealed a 
bimodal distribution with particle size ranging from 0.6 up to 110 µm, 
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as seen in Figure 2. The mean particle size was around 29 µm. The 
chemical composition of 58S MBG powder particles was quite similar 
to the expected composition (58.2 ± 2 wt% SiO2, 33.01 ± 1 wt% CaO, 9 
± 1 wt% P2O5), as detected by EDX analyses. The EDX spectra of all 
compositions are shown in Figure 3. The EDX spectra showed the 
highest intensity peak for Si element. The intensity of Ca element is 
intermediary while the peak for P element was the lowest in the spectra. 
Furthermore, the bioactive glasses embedding CaBr2 revealed an 
increase in the Br peak with the increase of CaBr2 in the composition.  
 
Figura 2. 58S BG Bimodal particle size distribution 
XRD spectra for the powders and heat pressed 58S bioactive 
glass samples free of CaBr2 are shown in Figure 4 while XRD spectra 
for samples embedding CaBr2 are shown in Figures 5 and 6. The XRD 
spectra of the bioactive glass powders revealed a broad diffraction band, 
confirming its amorphous and glassy nature [4,31,32]. Moreover, peaks 
of tetracalcium phosphate (TTCP), dicalcium silicate (DCS) and 
bromine oxide were identified that confirmed the success of the 
modified sol-gel synthesis. The increase of bromine phases was noticed 
with increasing of the amount of CaBr2 in the bioactive glass 
composition. Considering the crystalline phases, XRD peaks for calcium 
phosphate phases, wollastonite, pseudowollastonite and quartz were 
detected as tresult from the high heat treatment [32–36]. 
63 
Pseudowollastonite is a polymorph of wollastonite, that possesses a 
transition temperature around 1250 ºC. However, the excess of SiO2 
favors the formation of the pseudowollastonite at lower temperatures 
[35,36]. In the case of the XRD spectra for BG58S 5%CaBr2, the 
crystalline phases of quartz, tricalcium phosphate, wollastonite and 
phosphorus bromide were detected after 1150 ºC. The increase in the 
crystallization intensity of quartz can be explained by the decomposition 
of dicalcium silicate, in CaO and SiO2 [35,36]. Phosphorus bromide 
crystallizes from the decomposition of tetracalcium phosphate into β-
tricalcium phosphate, releasing phosphates to react with bromine oxide 
[35, 36]. In the case of the XRD spectra recorded for BG58S CaBr2 
10wt%, calcium phosphate silicate, pseudowollastonite, wollastonite 
and silicon bromide phases were detected after thermal treatment at 
1150 ºC. That indicated that the silicon was not available to crystallize 
alone and therefore it reacted almost on totality with the bromine oxide 
to crystallize silicon bromide. That can be associated with the excess of 
CaBr2 in such chemical composition. However, the thermal treatment 
promoted the formation of pseudowollastonite and wollastonite [32, 35, 
36].  
 
Figura 3. EDX spectra recorded for 58S bioactive glass free of CaBr2 and 
including 5 or 10% CaBr2 
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Figure 4. XRD spectra recorded for 58S bioactive glass samples free of CaBr2 
processed at 600 or 1150 
o
C.  
 
Figure 5. XRD spectra recorded for 58S bioactive glass samples embedding 5% 
CaBr2 processed at 600 or 1150 
o
C 
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Figure 6. XRD spectra recorded for 58S bioactive glass samples embedding 
10% CaBr2 processed at 600 or 1150 
o
C 
SEM images revealed 58S bioactive glass powder having an 
angular shape morphology that is typical from glass milling procedure 
(figure 7). BG58S samples containing CaBr2 5wt% before thermal 
treatment revealed needle like crystals typical from calcium phosphate 
phases [29]. Such crystals disappeared and formed angular lighter 
crystals like β-Tricalcium phosphate after thermal treatment at 1150 ºC 
[30]. Surfaces of bromide-doped 58S BG discs revealed a rough 
morphologic aspect associated with the content of CaBr2 as shown in 
figure 7. Thus, the presence of CaBr2 seemed to affect the densification 
process of the bioactive glass. Thermal treatment performed at a higher 
temperature and longer holding time should promote an increase in 
atomic diffusion rates, leading to the formation of larger and structural 
ordered particles.  
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Figure 7. SEM images of BG 58S 5wt % CaBr2 powder (A and B), 58S BG 
discs before (C, E and G) and after (D, F and H) thermal treatment 
incorporating 0, 5, and 10 wt % CaBr2 correspondingly  
The arithmetic average roughness (Ra) values and maximum 
height between peak and valley values (Rt) recorded on 58S BG discs 
increased with CaBr2 content as shown and illustrated in Figure 8.  The 
relative density of the samples were determined via Archimedes method 
before and after thermal treatment. Several thermal cycles were assessed 
at maximum temperature ranging from 600 up to 1250 oC in order to 
achieve a high density for the samples. A proper maximum temperature 
at 1150 ºC of thermal treatment was selected considering final shape and 
high density for microbiological assays. The relative density of the 
samples before the thermal treatment was higher than 50%. 
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Additionally, the relative density of those samples increased with the 
CaBr2 content. In a similar way, the sintered samples had a relative 
density of more than 74%, which increased directly with the CaBr2 
content, achieving around 95% relative density on the highest 
concentration of CaBr2 (Figure 9).   
 
Figure 8. Ra, Rt roughness values, color map and 3D representation of surface 
roughness for 0, 5, and 10wt% CaBr2 doped 58S BG discs after thermal 
treatment up to 1150
o
C 
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Figure 9. Relative densities of green and sintered discs of BG 58S containing or 
not 5wt% or 10wt% CaBr2 
Biofilm Inhibition   
A significant biofilm inhibition, represented by the decrease of 
bacterial cell amount, was noticed when the chlorhexidine was placed in 
contact with the multi-species biofilm grown on the 58SBG discs free of 
CaBr2. That validated the antimicrobial effect of chlorhexidine against 
all the early, beneficial and pathogenic species tested in this study. The 
amount of bacteria also decreased in the presence of 58SBG discs doped 
with 5% CaBr2 regarding S. mitis and S. gordonii (early colonizers), V. 
parvula and A. viscosus (beneficial species), and P. gingivalis 
(pathogenic species). However, no decrease of bacterial amount was 
detected for multi-species biofilm grown on 58S BG discs doped with 
10wt% CaBr2. Results of biofilm inhibition obtained by q-PCR analyses 
for early, beneficial, and pathogen bacteria are shown in Figures 10 and 
11.  SEM inspection of the 58S BG discs surfaces covered with multi-
species biofilms is shown in Figure 12. Considering the morphology of 
the multi-species biofilm tested in the present study, streptococcus, 
bacillus, and filamentous species can be detected on bioactive glass 
surfaces free or containing CaBr2 after 24h of multi-species biofilm 
growth (Fig. 12). The multi-species biofilm revealed similar 
morphological aspects on all the test samples inspected by SEM.   
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Figure 10. . Inhibition of early and beneficial oral biofilm species on 0wt% 
CaBr2 58S BG discs with chlorhexidine (CHX) (positive control group), 0wt% 
CaBr2 BG58S discs (negative control group), 5 or 10 wt% CaBr2 BG58S discs 
 
Figure 11. Inhibition of pathogen oral biofilm species on 0wt% CaBr2 BG58S 
discs with chlorhexidine (CHX) (positive control group), 0wt% CaBr2 BG58S 
discs (negative control group), and 5, 10 wt% CaBr2 BG58S discs 
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Figure 12. SEM images of multi-species biofilm adherence on BG58S discs 
with 0wt%CaBr2 (A,B), 5wt% CaBr2(C,D) and 10 wt% CaBr2(E,F)  
3.4 DISCUSSION   
The present study incorporated calcium bromide as a potential 
anti-biofilm compound into BG composition, which for the first time 
has been explored in tissue engineering applications. Accordingly, the 
results of this study has supported the hypothesis that BG modified with 
calcium bromide is able to inhibit different bacteria in multi-species oral 
biofilm revealed by real time q-PCR analysis. This study demonstrated 
an appropriate chemical and bimodal size distribution of BG particles 
and that BG samples embedding 5wt% CaBr2 had an anti-biofilm effect 
against early, beneficial and pathogen oral biofilm species.  
BG embedding 5wt% CaBr2 had a notorious anti-biofilm effect 
against species such as S. mitis, S. gordonii, A. viscosus, V. parvula, and, 
P. gingivalis. Conversely, no biofilm inhibition was distinguished for 
BG samples embedding 10wt% CaBr2, probably due to the higher 
roughness values revealed by the discs surfaces corresponding to this 
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experimental group. A high roughness seemed to affect negatively the 
anti-biofilm potential. Previous studies have reported that surfaces with 
higher roughness have more compatibility with biofilm adherence 
because bacteria is sheltered against shear forces. Additionally, biofilm 
adhesion area increases with the increment of roughness, which allows 
biofilm accumulation [39–41]. SEM analysis of biofilm adherence in the 
disk samples of this study did not show differences between the control 
and experimental groups; nevertheless, this is a qualitative analysis 
which only reveals the presence of certain species and is not as precise 
as q-PCR analysis.  
Furthermore, tissue engineering has been challenged to improve 
BG chemical composition considering biocompatibility and antibacterial 
effects. In the present study, the crystalline phases analysis revealed the 
presence of bioactive phases for bone healing such as tetracalcium 
phosphate and dicalcium silicate [32,34,37]. Regarding BG58S 5wt% 
CaBr2 processed at 1150 ºC, the XRD spectra (Fig 5) also revealed the 
presence of phosphorus bromide. Phosphorus tribromide is a compound 
used in pharmacology as an active compound of anti-inflammatory, 
analgesic and antipyretic reactions. Also, BG58S CaBr2 5wt% presented 
the crystal microstructures typical from calcium phosphates phases, 
which is an indication of a high bioactivity.   
Several previous studies have shown suitable antibacterial 
properties achieved by bioactive glasses doped with diverse oxides [10-
12]. However, possible toxic effects caused by metallic ions and 
particles embedded into BG are still a controversial concern for clinical 
applications. Most studies have tested antibacterial properties of 
modified bioactive glasses against planktonic bacteria solely [7,15,42]. 
Goh et al. reported that BG samples modified with 5 and 10 mol% 
cerium oxide demonstrated a significant antibacterial activity against E. 
coli, evaluated by the quantitative viable count method [14]. 
Additionally, El-Kady et al. established in their study that all BG 
nanoparticles doped with 1, 3, 5, and 10wt% Ag2O had antibacterial 
effect against S. aureus and E. coli cultures evaluated by the disk 
diffusion method. That study attributed the high effective antibacterial 
effect to the presence of silver ions [13]. In contrast, Fooladi et al. stated 
that silver is not an essential component for inhibiting bacterial growth 
[24]. That study incorporated MgO into BG nanopowders and its 
antibacterial effect was assessed against E. coli, P. aureginosa, and S. 
aureus. The BG nanopowders at a greater concentration than 15.62 
mg/mL showed efficient inhibitory effects on the three bacterial strains. 
As well, selenium nanoparticles have also being added to BG as an 
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antibacterial agent. Stevanovic et al. showed in their study that BG 45S5 
with selenium nanoparticles had a significant antibacterial activity 
against S. aureus and S. epidermis cultures, and inhibited B. subtilis and 
K. pnuemoniae growth [23]. Fluorine has also being added to BG 
particles as an antimicrobial agent. Xu et al. showed in their study that 
BG particles mixed with sodium fluoride (NaF) had a significant S. 
mutans  biofilm inhibition effect after 24 hours of exposure. That study 
tested the anti-biofilm effect against one oral bacteria (monospecie 
biofilm); nevertheless, currently there are not enough studies testing 
modified bioactive glass against multi-species oral biofilms. Fluorides 
are known to inhibit bacterial enzymes like enolase and catalase. Also, 
compounds with fluorine may disrupt bacterial cell membranes and 
cytoplasm pH, and interfere glycolysis of cariogenic bacteria [15]. 
Bromine has many similar characteristics to fluorine although bromine 
has not being incorporated into BG composition as an antibiofilm agent 
in previous studies. Considering a lack of findings on the effect of Br 
based compounds, this study pursued the objective of testing bromide 
doped BG as a new repairing biomaterial to inhibit multispecies oral 
biofilm.   
The results of the present study are promising since bromide had 
an anti-biofilm effect against early, beneficial, and pathogen oral 
species. Nevertheless, future studies evaluating anti-biofilm properties 
of CaBr2 doped BG samples should take in consideration that samples 
characteristics, such as surface roughness are of extreme importance 
regarding biofilm adherence. One limitation of the present study was 
that samples of the tested groups had different surface roughness values; 
consequently, biofilm inhibition was evaluated under different 
circumstances in each study group.  
In addition, forthcoming studies should evaluate the 
biocompatibility and the hydroxyapatite formation capability of 
innovative bromide doped BG to be tested in future in vivo studies. 
Regarding the mechanism in which bromine acts as anti-biofilm agent, 
new studies should analyze how bromine ions are able to affect biofilm 
formation and additionally include clinical strains isolated from patients 
reporting infection in implanted sites to mimic conditions that are more 
realistic to clinical complications.    
3.5 CONCLUSION 
Within the limitations of this study, the main outcomes of this 
work are drawn as follow:  
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• The chemical composition of the CaBr2-doped bioactive 
was monitored and therefore the powder particles showed 
an angular shape and bimodal size distribution. That plays 
an important role on the clinical application in bone defects; 
• Considering microbiological assessment, bioactive glass 
doped with 5wt% CaBr2 had a considerable anti-biofilm 
effect against oral bacteria involved in a multi-species 
biofilm. Such findings are more representative concerning 
the aggregation pathways among different species when 
compared to mono-species methods related in literature. In 
fact, biomaterials embedding potential antibiofilm 
compounds must be tested against multi-species biofilms as 
reported in the present study  
• CaBr2-doped bioactive glass can be considered an 
advantageous anti-biofilm biomaterial for clinical 
applications and treatment of oral infections at implanted 
surgical sites. Notwithstanding, other bromide contents and 
compositions should be assessed by physicochemical and 
biological tests in further studies to clarify the anti-biofilm 
behavior of such enhanced bioactive glasses.     
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Abstract:  
Bioactive glasses are attractive materials for bone repairing procedures 
due to their desirable osteoconductive, angiogenic, osteogenic, and 
antibacterial properties.  In addition, the antibacterial properties of 
bioactive glass can be enhanced depending on the glass porous structure 
and chemical composition. The aim of the present study was to evaluate 
the chemical reactivity of 58S mesoporous bioactive glass free or 
embedding propolis and cranberry antibiofilm compounds at different 
concentrations. Mesoporous 58S bioactive glass (MBG) was synthesized 
by alkali sol-gel method with the addition of the triblock pluronic 
copolymer P123 as surfactant. Samples were characterized by physco-
chemical properties measurement, N2 adsorption/desorption analysis, 
and field emission scanning electron microscopy (FESEM) 
observations. MBG powders were immersed into 5 and 10 µg/ml 
propolis or cranberry solutions for 24 h. The chemical reactivity of the 
specimens was evaluated by FESEM, EDX, FTIR and Ca/P analysis 
after being immersed in simulated body fluid (SBF) solution for 8, 24 
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and 72 h. MBGs had the expected chemical composition with a particle 
size distribution ranging from 1.44 up to 955 µm, and a mean particle 
size of 154 µm. MBG particles exhibited a pore volume of 0.8 cc/g, a 
pore radius of about 2 nm and a surface area at 350.2 m
2
/g, according to 
BJH and BET analyses. A hydroxyl-carbonate apatite (HCAp) layer was 
formed on all samples after SBF immersion for 72 h. Pure MBG showed 
the highest chemical reactivity after 72 h and therefore the resulting 
apatite layer revealed a Ca/P ratio of 1.8, corresponding to non-
stoichiometric biological apatite. MGB embedding propolis and 
cranberry can be considered for future microbiological analysis since 
their modified composition did not interfere with the ability of MBG to 
develop a HCAp layer on its surface, which is an  essential property for 
bone regeneration applications. 
Key words: mesoporous bioactive glass, anti-biofilm, sol-gel synthesis, 
bioactivity, propolis, cranberry PACS, bone healing 
4.1 INTRODUCTION  
More than 45 years ago, Hench et al. developed the first bioactive 
glass (BG) of composition: (46.1 mol.% SiO2, 24.4 mol.% Na2O, 26.9 
mol.% CaO and 2.6 mol.% P2O5); with the purpose of generating a 
biomaterial that could bond to bone fulfilling the requirements of 
orthopedic surgeries of the time[1]. After many years of bioactive glass 
intensive research, BGs have been demonstrated to be outstanding 
materials due to their desirable characteristics such as high bioactivity, 
osteogenic stimulation, angiogenic effect, ability to bond to soft tissues, 
high biocompatibility and antibacterial activity induced by its ion 
release capability [2–10]. It is well established that highly bioactive 
synthetic glasses bond to bone through the formation of a hydroxyl-
carbonate apatite (HCAp) layer which mimics the mineral phase of 
bone; thus, resulting in a biological match between BGs and bone 
tissues [3,10]. Certainly, bioactivity accomplished through a high 
chemical reactivity in contact with human tissues  is the most acclaimed 
property of bioactive glasses; nevertheless, new tissue engineering 
requirements have emerged besides this property to fulfill the necessities 
of surgical and regenerative procedures which include also applications 
in soft tissue repair [6,7,9].  
Several new BG compositions have been developed over the 
years to improve bioactivity and mechanical properties[6,10]. Recent 
advances have considered BG structures characterized by nano-porous 
organized arrangements, known as mesoporous bioactive glass (MBG), 
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which are developed by the sol-gel method [11–14]. MBGs exhibit large 
surface area with organized nano-porous channels which can induce a 
higher HCAp formation and allow the incorporation of bioactive 
molecules such as bone morphogenetic proteins (BMP) and vascular 
endothelial growth factor (VEGF) to induce osteogenesis and 
angiogenesis [12,14]. Furthermore, MBGs can act as drug delivery 
systems by the incorporation and release of antibiotics, antibacterial and 
antibiofilm compounds in their nano porous structure [11,12,14,15].  
Studies have reported that orthopedic and craniofacial surgeries 
have a considerable risk of postoperative bone infection and that bone 
implant associated infections are major complications of bone repairing 
procedures [4,5,16–18]. Systemic antibiotic therapy is the most common 
treatment of bone-associated infections. However, such therapy can 
cause a bacterial resistance of pathogenic species considering the 
formation of biofilms [14]. It should be highlighted that biofilms consist 
of a well-organized microbial community embedded in an extracellular 
polymeric matrix composed of polysaccharides, nucleic acids, proteins 
and water  being  the main cause of implanted bone infections 
[17,19,20]. Bacteria organized in a multispecies biofilm is 1000 times 
more resistant to antibiotics when compared to planktonic bacteria [19]. 
Thus, BGs have been considered as favorable biomaterials to locally 
counteract grafted or implanted site infections due to their antibacterial 
effect accomplished by raising the pH of the medium, which affects 
planktonic bacterial growth [8]. Only few studies have reported the 
effect of BG on multispecies  biofilm as found in the oral cavity [4,21]. 
Several antibiotics such as gentamicin, teicoplanin, tetracycline, 
vancomycin, and cefuroxime axetil [22–26] have being loaded into 
MBGs leading to favorable antibacterial effects. However, the 
antibiofilm effect of MBG loaded with antibiotics has not been 
completely validated in these studies. Hence, it is of clinical relevance to 
incorporate antibiofilm rather than antibacterial compounds into MBG 
for an effective infection treatment [27].  
Previous studies have reported the incorporation of natural 
derived antibiofilm compounds into BG and MBG [28–30]. Surface 
functionalization of BGs has been explored for the incorporation of 
natural biomolecules such as polyphenols, which have potential 
antibacterial benefits[30]. Additionally, a herbal derived substance 
called propolis, which is a resinous natural substance collected by bees, 
has being described to have several health promoting properties like 
fibroblast stimulation, antioxidant activity, antifungal and antiviral 
activity, antibiofilm inhibition and counteraction  of bacteria virulent 
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factors [29,31]. Propolis has shown non-cytotoxic effects, but it has not 
been deeply explored in tissue engineering applications [32,33]. Only 
one study [29] has incorporated red and green propolis collected from 
different regions into BG, showing a satisfactory growth inhibition of  S. 
aureus, E. faecalis, S. mutans, P. intermedia, F. nucleatum, P. 
gingivalis, and, A. actinomycetemcomitans. Moreover, other natural 
compounds, such as A-type proanthocyanidins (PACS) derived from the 
cranberry fruit (Vaccinium macrocarpon) have also demonstrated a 
potential antibiofilm effect[34]. Initially, cranberry PACS were widely 
studied to prevent and treat urinary tract infections since they prevent 
bacterial adhesion to uroepithelial cells [34,35]. Additionally, Kim et al. 
reported that PACS are capable of inhibiting bacterial adhesion on the 
exopolysaccharide (EPS) matrix which provides biofilm mechanical 
stability for microbial proliferation [36]. Other studies have also shown 
that cranberry PACS neutralize S. mutans virulence factors and increase 
the medium pH leading to changes of biochemical and ecological factors 
for cariogenic biofilm development [37,38]. On the other hand, even 
though several studies have reported the antibiofilm potential of 
cranberry PACS[34–38], that compound has not been incorporated into 
biomaterials to treat bone-derived infections and for bone regeneration.  
Accordingly, this study pursuits to integrate natural derived 
antibiofilm substances in bioactive glasses. In particular, a novel 
mesoporous bioactive glass incorporating propolis and cranberry 
antibiofilm compounds was developed. The hypothesis behind this work 
is that the incorporation of propolis and cranberry compounds will not 
affect the inherent bioactivity of 58S mesoporous bioactive glass, 
developing thus a material , which is both effective against biofilm 
formation and suitable to bond to bone without addition of antibiotic 
drugs.  
4.2 MATERIALS AND METHODS    
4.2.1 MBG sol-gel synthesis  
MBG (58 wt% SiO2, 33 wt% CaO, 9 wt% P2O5) (58S 
composition) powder was processed via a sol-gel technique. First, 4 g of  
pluronic triblock copolymer P123 (EO20PO70EO20, 5800, Sigma 
Aldrich, USA) surfactant was dissolved in 50 mL ethanol by using a 
stirring bar at 40 
◦
C for 1 h. Afterwards, tetraethyl orthosilicate (TEOS) 
(98%, Sigma Aldrich, USA), triethyl phosphate (TEP) (99.8%, Sigma 
Aldrich, USA) and calcium nitrate tetrahydrate (Ca(NO3)2·4H2O) 
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(Vetec, Brazil) were added to the solution as precursors of silicon, 
phosphorous and calcium oxide. The solution was stirred at  40
◦
C for 12 
h. Nitric acid (HNO3, 68%, Vetec, Brazil) was used to dissolve 
Ca(NO3)2·4H2O and to adjust the pH of the solution while ethyl alcohol 
(EtOH, P.A., Synth, Brazil) was used to dissolve P123, TEOS and TEP. 
The molar ratios of SiO2, P2O5 and CaO were calculated, concerning the 
58S MBG proportion. TEOS and TEP were placed in a glass recipient 
containing EtOH under magnetic stirring at 25 
o
C for 10 min. 
Ca(NO3)2·4H2O was dissolved in 2 M HNO3 and then added to water at 
a molar ratio TEOS:H2O of 1:4. Then, the solution was placed for 
drying in a chamber at 70 °C over a period of 24 h. Subsequently, the 
dried gel was thermally treated at 600 °C for 6 h at a heating rate of 
1ºC/min to remove the organic agents and the surfactant template. The 
methodology used in this study is schematically shown in Figure 1. 
 
 
Figure 1. Schematic diagram showing the methodology applied in this study to 
prepare MBG incorporating propolis and cranberry PACS.  
4.2.2 Physicochemical characterization  
The particle size distribution was measured in a laser diffraction 
equipment (Mastersizer 2000, Malvern, UK). The powder was 
introduced in a wet dispersion unit with low water rotation (~1200 rpm) 
to avoid significant agglomeration of the particles. 
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Chemical analysis of the samples was performed using energy 
dispersive X-ray spectroscopy (EDX, Swift 2000, Hitachi, Japan). The 
compound composition was obtained by rearranging the quantity of 
oxygen to calculate the weight percentage of oxides using the most 
stable stoichiometric arrangement, resulting in a reliable tool to semi-
quantify the respective oxides. The functional groups of the powder 
samples were identified by Fourier transform infrared spectroscopy 
(FTIR, Cary 600 Series, Agilent technologies, USA), performed by KBr 
pellet technique. Pellets were prepared by mixing 1 mg of each sample 
powder and 300 mg KBr at infrared grade under vacuum. The infrared 
spectra were recorded in a wavenumber of 400-4000 cm
-1
 in 
transmission mode with 32 scans and resolution of 4 cm
-1
. 
MBG textural analysis was performed by N2 adsorption and 
desorption isotherms measured by a porosity analyzer (AUTOSORB-1-
1 C, Quantochrome) at -203.85
◦
C. Pore size distribution and volume 
were determined from the isotherm adsorption branch applying the 
Barrett-Joyner-Halenda (BJH) method while the surface area was 
established by the Brunauer-Emmett-Teller (BET) method. The 
morphologic aspects of the MBG particles were analyzed by field 
emission gun scanning electron microscopy (FESEM) (Zeiss Leica, 
Germany) at an acceleration potential of 5 kV.  
4.2.2 In vitro loading of propolis and cranberry compounds  
Green propolis dry extracts from Baccharis dracunculifolia sp. 
(Natucentro®, Minas Gerais, Brazil) and Cranberry PAC dry extracts 
from Vaccinium macrapon sp. (Naturex-DBS® , Massachusetts, USA) 
were diluted in a 50% (v/v) hydro-alcoholic solution (EtOH, P.A., 
Synth, Brazil) under magnetic stirring at room temperature for 5 h to 
prepare solutions of 5 and 10 μg/mL as described in a previous study 
[31].  Then, 0.5 g of MBG powders were immersed into 50 mL of the 
corresponding solutions with different concentrations and stirred at 37°C 
for 24 h. MBG powders were also added into a hydro-alcoholic solution 
free of natural derived compounds to prepare the control group. After 
immersion, the solutions containing MBG powders were centrifuged 
and dried in a vacuum oven at 40 °C for 3 h.  
4.2.3 In vitro apatite-forming assays  
Simulated body fluid (SBF) solution was prepared following 
Kokubo´s method [39]. The chemical composition of the SBF solution 
is shown in Table 1. MBG powders (75 mg) were immersed into 50 mL 
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of SBF solution in sterilized PS flasks. The flasks were placed in an 
incubator (IKA, Germany) at 37°C and stirred at 90 rpm for 8, 24 or 72 
h. At the end of each period, the samples were centrifuged, removed by 
filtration, washed with deionized water and dried in a vacuum oven at 
37°C for 24 h [40]. Each sample was run in triplicate. Afterwards, the 
HCAp-forming ability of all samples was evaluated by SEM, EDX, and 
FTIR analysis.  
Table 1.  Chemical composition of the SBF stock solution [40] 
ORDER  REAGENT  AMOUNT (g/l) 
1 NaCl 8.035 
2 NaHCO  0.355 
3 KCl 0.225 
4 K2HPO4 3H2O 0.231 
5 MgCl2 6H2O 0.311 
6 HCl 1M 38 mL 
7 CaCl2 2H2O 0.386 
8 Na2SO4 0.072 
9 Tris  6.118 
4.3 RESULTS    
4.3.1 Characterization of MBG particles 
MBG particle size ranged from 1.44 up to 955 µm, revealing a 
Gaussian-like distribution, as seen in Figure 2A. The mean particle size 
was around 154 µm. The actual chemical composition of 58S MBG 
particles was close to the expected composition (58.22 ± 2 wt% SiO2, 
33.091 ± 3 wt% CaO, 8.6 ± 1 wt% P2O5) as shown in Figure 2B. EDX 
spectra showed the highest intensity peak for the Si element, followed 
by Ca element and P element (Figure 2B).  
The FTIR analysis showed BG characteristic peaks of Si-O-Si 
where the main absorption bands were at 1080, 810 cm
-1
, attributed to 
the Si-O-Si asymmetric stretching, and at 460 cm
-1
 attributed to Si-O-Si 
bending, as demonstrated in Figure 3.  
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Figure 2. (A) MBG 58S particle size distribution and (B) EDX results for 58S 
MBG. 
The textural analysis regarding N2 adsorption-desorption 
isotherms, BJH pore size distribution and volume are shown in Figure 4. 
58S MBG N2 adsorption-desorption isotherms (Figure 4A) corresponded 
to a type IV curve of the International Union of Pure and Applied 
Chemistry (IUPAC) classification which is typical of mesoporous 
materials showing a H1 type hysteresis loop [41]. The initial part of this 
curve can be associated to monolayer-multilayer adsorption. Also, a 
limiting uptake in a range of high P/Po was noted[42]. In addition, the 
sharp steps in adsorption and desorption branches at 0.7-0.8 and 0.6-0.7 
P/Po regions respectively, are associated to capillary condensation at 
mesopores. The BHJ method revealed that MBG particles had a mean 
narrow pore radius at 2 nm, as shown in Figure 4B, and a porosity 
volume of about 0.83 cc/g. The MBG specific surface area was 350.2 
m
2
/g according to BET analysis.  
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Figure 3. FTIR spectrum obtained for 58S mesoporous bioactive glasses 
(relevant peaks are indicated). 
 
Figure 4. (A) N2 adsorption (red)-desorption (blue) isotherms and (B) BJH pore 
radius distribution curves for 58S mesoporous bioactive glass particles.  
FESEM micrographs revealed a fairly regular and uniform 
appearance of MBG particles, as seen in Figure 5A. At higher 
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magnifications, MBG particles showed an angular shape and non-
smooth porous structure, having pores below 10 nm in diameter, as 
observed in Figure 5B and 5C. Also, sphere-like structures below 100 
nm are noticed in Figure 5C, probably indicating crystallized β-
Tricalcium phosphate which may have formed after thermal treatment of 
the samples as described elsewhere [4].  
 
Figure 5. (A-C) FESEM images of 58S MBG 58S particles at different 
magnifications. In (C) nano-pores (white squares) are revealed at 80,000X 
magnification.   
4.3.2 In vitro apatite-forming assays  
FESEM images revealed that the surface of all samples was 
relatively smooth and did not exhibit any HCAp formation after 
immersion in SBF for 8 h (Fig. 6). After 24 h, all MBG samples 
changed their surface morphology having a more granular-like 
appeareance. For 72 h of immersion, all samples showed spherical-like 
structures which indicates the formation of apatite crystals. The control 
58S MBG  particles showed an apatite layer formed over their surface 
upon 24 h of immersion in SBF, as seen in Figure 6A whereas almost all 
MBG particles were covered with an HCAp layer. MBG particle 
surfaces were covered with a thick HCAp layer revealing spherical, 
needle, polygonal, and cauliflower-shaped crystals.  
In the case of MBG particles embedding 5 µg/ml cranberry 
PACS, an increase of roughness seemed to take place after 24 h 
immersion in SBF. Also, the surface was covered with sphere-shaped 
apatite crystals after 72 h of immersion in SBF, as seen at higher 
magnification (Figure 6B, white squares). In the case of MBG 
embedding 10 µg/ml cranberry PACs, the sample surface was still 
smooth after 24h of immersion when compared to the control group. 
Only some round plain structures could be detected on MBG embedding 
10 µg/ml cranberry (Figure 6C). On FESEM micrographs, MBG 
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particles embedding 10 µg/ml cranberry showed the lowest HCAp 
formation after 24 h among all samples. After 72 h of immersion, the 
surface of MBG embedding 10 µg/ml cranberry was not smooth 
anymore due to the presence of numerous small rounded apatite 
structures (Fig. 6C).  
MBG particles embedding both propolis concentrations are 
shown in Figures 6D and 6E. Both samples showed the development of 
an HCAp layer after 24 h of immersion in SBF that was more noticeable 
when compared to the other experimental group samples. After 72 h, a 
cauliflower shaped apatite layer could be clearly detected for both 
MBG/propolis containing samples, as seen in Figure 6D and 6E at the 
highest magnification micrographs (white squares).  
EDS analyses were performed in triplicate for all samples to 
determine the Ca/P atomic ratio, as shown in Table 2. The EDS spectra 
analysis showed non-significant changes in MBG composition for all 
samples after immersion in SBF for 8 h (Fig. 7). After 24 h, EDS 
showed an increase in Ca and P wt% while Si wt% decreased in all 
samples. Generally, MBG samples showed a notorious Si wt% loss and 
a higher wt% P after immersion in SBF for 72 h. EDS analysis on MBG 
embedding 5µg/ml propolis revealed Si as the main element followed by 
Ca and P after immersion in SBF for 8 h (Fig. 7A). However, a decrease 
in Si content and increase in P and Ca concentrations are noticed after 
24 immersion in SBF (Fig. 7B). This result can be linked to the presence 
of a thick HCAp layer as shown in the SEM micrograph. Finally, after 
72h, figure 7C shows an EDS spectrum exhibiting a lower Si wt% and 
higher P wt% corresponding to the formation of HCAp, which is 
expected after immersion in SBF for 72 h (Fig. 7C), as seen by SEM 
micrographs. The Ca/P ratios shown in Table 2 indicate that the 
unloaded MBG sample reached a Ca/P ratio of 1.8 after immersion in 
SBF for 72h, which is in accordance to non-stoichiometric HCAp ratio 
[43]. The samples embedding propolis in both concentrations revealed 
Ca/P ratios close to the HCAp reference value after 72 h of immersion 
in SBF. MBG sample embedding 5 µg/ml of cranberry PACs showed a 
ratio of 2.03 although MBG embedding the higher cranberry PACs 
concentration had a Ca/P ratio of 2.85.  
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Figure 6.FESEM micrographs at 10,000X recorded on 58S MBG particles after 
immersion in SBF for 8, 24 and 72 h. MBG (A) Pure and containing (B) 5 
µg/ml cranberry PACS, (C) 10 µg/ml cranberry PACs, (D) 5µg/ml propolis 
and (E) 10 µg/ml propolis. Red squares exhibit corresponding micrographs at 
50,000X.  
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Figure 7. SEM images (1,000X) and EDX analysis recorded on MBG 
containing 5 µg/ml propolis particles immersed in SBF solution for (A) 8 h, (B) 
24 h and (C) 72 h.  
Table 2. Ca/P elemental concentration ratio of samples before and after SBF 
immersion for 0, 8, 24 and 72 h  
 
The samples of the present study after 8 and 24 hours of SBF 
immersion did not show significant compositional changes in the FTIR 
spectra. The FTIR spectra of MBG with 5 or 10 µg/ml of propolis and 
cranberry PACS were similar after 72h of immersion. Figure 8 exhibits 
the spectra for MBG incorporating 5 µg/ml for both compounds.  The 
FTIR spectra of all samples presented the characteristic peaks attributed 
to HCAp layer formation as a doublet at around ~600 cm
-1 
corresponding to the bending mode of crystalline phosphate P-O and P-
O stretching mode at ~1050 cm
-1
, where the resonance was more intense 
especially for the spectrum of  pure MBG. On the other hand the 
spectrum of MBG before SBF immersion indicates the absence of the 
mentioned double peak. Additionally, resonances attributed to the 
phosphate group were present in the spectra of pure MBG, MBG/ 
cranberry PACS and MBG/propolis. A narrowing band at around 820 
cm
-1
 corresponds to the bending mode of C-O and at around 1400cm
-1
 a 
Time   
SBF 
(h) 
MBG 
58s 
 
MBG/prop 
5 µg/ml 
MBG/prop 
10 µg/ml 
MBG/PACS 
5 µg/ml 
MBG/PACS 
10 µg/ml 
0  7.16 ± 1 6.67 ± 1 6.56 ± 1,5 8.1 ± 1 7.03 ± 1 
8  4.89 ± 2 5.7 ± 2 6.02 ± 1 7.3 ± 1,5 7.01 ± 2.5 
24  2.01 ± 1 4.08 ± 1.5 5.08 ± 1 6.04 ± 1 6.07 ± 1.5 
72  1.81±1.5 1.9 ± 1.6 2.01 ± 1.5 2.03 ± 2 2.85 ± 1 
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peak corresponding to the C-O stretching mode can also be observed in 
the pure MBG spectrum. In addition, at ~1680 cm
-1
 the resonance 
corresponding to C-O in CO3
2-
 can also be observed indicating the 
formation of a carbonated HAp due the presence of CO2 in SBF. 
 
Figure 8.  FTIR spectra obtained for 58S mesoporous bioactive glass samples 
(free MBG, MBG-5 µg/ml propolis and MBG-5 µg/ml cranberry PACS) 
before and after 72 h of SBF immersion. (Red circle identifies the double peak 
characteristic of HCAp formation) 
4.4 DISCUSSION  
The present work synthesized mesoporous bioactive glass 
incorporating propolis and cranberry compounds in order to enhance the 
bioactive properties and anti-biofilm potential of MBG for bone healing 
and infection treatment procedures. The results of the present study 
supported the hypothesis that natural derived compounds incorporated 
into MBG did not interfere with the inherent bioactivity of this 
biomaterial. This study demonstrated an appropriate physical, chemical, 
and particle size distribution of MBG samples. Moreover, the addition 
of the surfactant P123 to the sol gel synthesis did not change the 
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characteristic chemical composition of 58S BG, as confirmed by EDX 
and FTIR analysis. 
Furthermore, the textural analysis showed that the synthesized 
MBG particles had a meso-porous structure of pore size of 4nm, with a 
high volume and specific surface area making it capable to incorporate 
in its structure therapeutic agents as a drug delivery system. The 
mesoporous structure of the synthesized MBG could be determined by 
its IV N2 adsorption and desorption isotherm curve with a H1-type 
hysteresis loop at high relative pressure according to the IUPAC 
classification [11,42]. The present study is supported by previous 
investigations showing the same type of hysteresis loop in the N2 
isotherms for mesoporous materials [12,14,44,45], however in this study 
the organization and arrangement of the meso-pores were not confirmed 
(e.g. by TEM). In addition, previous studies developing MBGs have 
shown higher surface area, pore volume, and pore diameter that should 
enhance the MBG capability to incorporate therapeutic agents in their 
nano-structure and favor a higher HCAp formation to bond with bone 
receptor tissues [46]. A high surface area increases the amount of Si-O 
bonds to interact with loaded therapeutic agent molecules and a high 
pore diameter and volume enables a larger space for drug load and 
sustained delivery. Furthermore, diverse biomolecules such as BMPs 
and VEGF can covalently bond to MBG surfaces to stimulate specific 
target cells for osteogenesis and angiogenesis  [46,47]. Even though the 
present study showed appropriate meso-pore characteristics, other 
structure directing agents could be applied such as F127, F108, P85, 
CTAB, and P123+CTAB, reported in other studies [12,48], to increase 
the surface area and volume of MBG improving in this way the 
mentioned therapeutic, bioactive and osteogenic characteristics [14].   
The simulated body fluid test is widely accepted to evaluate the 
bioactivity of a material in terms of its ability since it mimics the 
process in which a biomaterial is able to bond to bone tissues through 
the formation of a bone like apatite layer [39,40]. As follows, the 
mechanism of MBG apatite formation involves a series of steps. First, 
an exchange between calcium and hydrogen ions occurs. Consequently, 
silanol forms over the surface of the biomaterial and polymerizes 
producing an amorphous silica gel.  Afterwards, calcium and phosphate 
ions migrate to the newly formed silica gel and start forming an HCAp 
layer, which finally crystallizes forming needle and cauliflower-shaped 
structures which promote the attachment of bone cells [49]. In this 
study, MBG free or incorporating propolis and cranberry compounds did 
not exhibit apatite formation after 8 h in SBF solution; however, all the 
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samples were able to induce a significant HCAp layer after 72 h in SBF. 
Additionally, pure MBG samples revealed through chemical and 
microscopic analysis the greatest HCAp formation after 24 and 72 h, 
where their surface was completely covered by needle like and 
cauliflower-shaped crystals typical of the process of HCAp 
crystallization [43,50,51]. Nevertheless, MBGs immersed in propolis 
and cranberry solutions were also able to develop an HCAp layer after 
72 h. Only the highest concentration of cranberry PACS solution 
seemed to interfere with the HCAp forming capability of MBG 
particles. The highest concentration (10 µg/ml) of cranberry PACS 
negatively affected the bioactivity of the samples which can be observed 
in FESEM micrographs and Ca/P values comparable to 1.8 which 
corresponds to non-stoichiometric hydroxyapatite [43]. Furthermore, 
pure MBG, 5-10 µg/ml propolis and 5µg/ml cranberry MBGs had a 
Ca/P value close to 1.8 demonstrating the presence of HCAp. In 
addition, EDX analysis exhibited after 24 and 72 h a notorious increase 
of calcium and phosphate wt% in all samples indicating the formation of 
a calcium phosphate layer over MBG particles by the reaction of Ca
2+
 
and PO4
3-
 ions from SBF solution. These results are relevant for  the 
intended applications in bone regeneration, since released Ca, Si and P 
ions from MBG particles can improve cell proliferation through HCAp 
layer formation, as reported in previous studies [49,52]. Finally, FTIR 
analysis did not show any significant change in the chemical 
composition of the samples after 8 h of SBF immersion. MBG 
incorporating propolis and cranberry compounds at both concentrations 
exhibited similar FTIR spectra after 72 h in SBF. As shown in figure 8, 
FTIR spectra for all samples after 72 h showed characteristic peaks 
attributed to HCAp layer formation as other studies report [53,54]. 
Resonance bands attributed to P-O and C-O were observed in all 
samples especially in pure MBG particles. This chemical analysis 
supports FESEM observations, which indicated that samples were able 
to develop an HCAp layer after 72 h of SBF immersion. This 
observation has clinical relevance since this HCAp layer on MBG 
surface layers facilitates bone contact few days after the surgical 
procedure. 
BGs have been modified over the years with the incorporation of 
diverse antibacterial and antibiofilm agents to counteract bone infection. 
Various studies have reported the incorporation of metal oxides, 
antibiotics and other organic agents into bioactive glasses[11–16]; 
however, there is no consensus until present days of which antibiofilm 
agent is the most effective for bone infection treatment [8,41,55–57]. 
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Indeed, the BG S53P4 is being successfully commercialized to 
counteract osteomyelitis conditions [58–60]. Taking in consideration 
that some metal ions have toxic effects in the human body [61], the 
present study investigated for the first time embedding in MBG two 
natural derived antibiofilm components consumed by humans which 
have no toxic effects [33,35]. Propolis and cranberry antibiofilm 
compounds have complex and rich phytochemical compositions of 
diverse elements such as flavonoids, steroids, amino acids, phenolic and 
aromatic compounds, which vary in composition and quantity 
depending on their growing conditions [62,63]. For this reason, the 
present study used propolis and cranberry compounds that already had 
chromatographic analysis and were previously standardized for 
commercial distribution. A difficulty of this study was to develop a 
protocol to incorporate propolis and cranberry compounds into bioactive 
glass mesoporous structures since there are no previous related studies 
that have followed an established and replicable methodology. 
Consequently, this study followed standard methods to develop an 
―accurate‖ procedure to embed propolis and cranberry compounds into 
MBG through the immersion technique. In addition, the main objective 
of the present study was to evaluate the bioactivity of the modified 
MBGs since this is an essential and desired characteristic of this 
biomaterial. Further studies are required to understand the mechanisms 
in which these natural agents bond to MBG surfaces, how its delivery 
takes place and if their antibiofilm potential is effective to treat bone 
infections. Certainly, nature´s incomparable properties via antibiofilm 
compounds can be explored in novel biomaterial combinations, in this 
case with MBG, to develop a superior biomaterial system able to 
accomplish tissue-engineering goals with simultaneous anti-infection 
outcome. 
4.5 CONCLUSION  
The main conclusions of this study and perspectives for further 
reserach are the following: 
 
 MBG (58S) exhibited favorable physical properties, 
especially their mesoporous structure, that can act as a drug 
delivery system targeting specific areas where therapeutic 
agents are required, representing an alternative to systemic 
antibiotic therapy. 
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 All samples were able to induce an HCAp layer formation 
on MBG particles after 72 h of SBF immersion, which is 
important for clinical applications since such HCAp layer on 
MBG enables bone contact only few days after the grafting 
procedure.  
 The incorporation of propolis and cranberry PACS 
compounds reported as antibiofilm agents did not inhibit the 
HCAp formation ability of MBG, thus imparting their 
antibiofilm properties for bone repair and infection 
treatment. 
 Further studies are needed to assess the effects provided by 
the antibiofilm agent confined and delivered through MBG 
nano-pores and to develop release triggers such as pH, 
temperature, and light, which could make the delivery 
system more effective and sustained. 
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5 CONSIDERAÇÕES FINAIS  
O biovidro ativo tem sido desenvolvido para diversas aplicações 
nos processos de reparo e tratamento de infecção óssea. No em tanto, o 
biovidro ativo tem suas limitações para o tratamento de infecções nos 
leitos receptores que têm como fator causal a aderência do biofilme 
multi-espécies. Consequentemente a engenharia tecidual tem 
modificado o biovidro ativo incorporando na sua estrutura tanto química 
como física agentes anti-biofilme orgânicos e inorgânicos. Nos últimos 
anos, as diferentes moléculas derivadas de óxidos de metal, antibióticos 
e outros agentes sintéticos incorporadas no biovidro ativo têm dado 
resultados satisfatórios antimicrobianos, mas não têm apresentado 
resultados concluintes com respeito à inibição do biofilme. Assim, o 
presente trabalho explorou o estado da arte do tema para desenvolver 
assim partículas do biovidro ativo 58S normal e mesoporoso 
incorporando moléculas de brometo, cranberry e própolis a fim de 
combater as infeções ósseas associadas ao biofilme. Em princípio, o 
biovidro ativo 58S incorporando brometo mostrou resultados 
promissórios com relação a inibição de biofilme oral multi-especies. Por 
outro lado, o biovidro mesoporoso incorporando as moléculas naturais 
mostrou uma alta bioatividade que é uma característica inerente do 
biomaterial, sendo assim um material promissório que poderia atuar 
como sistema de liberação localizado de agentes anti-biofilme no leito 
receptor. Contudo, futuros estudos são necessários para estabelecer os 
agentes anti-biofilme mais efetivos para tratar as infeções ósseas que 
possam ser incorporados no biovidro ativo sem interferir com sua 
bioatividade inerente, nem causar efeitos citotóxicos no leito receptor.  
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